Expression of activated molecules on CD5 super(+)B lymphocytes in autoimmune hemolytic anemia

To investigate the expression of activation molecules on CD5 super(+)B lymphocytes in peripheral blood of autoimmune hemolytic anemia (AIHA)/Evans patients. The expression of CD80, CD86, and CD69 on CD5 super(+)B lymphocytes was detected using flow cytometry in 30 AIHA/Evans patients, 18 normal controls (NC) and nine chronic lymphocytic leukemia (CLL) patients. CD80 on CD5 super(+)B lymphocytes in untreated patients was higher than that in remission patients (P < 0.05), NC (P < 0.01) and CLL patients (P < 0.01). CD80 on CD5 super(+)B lymphocytes was higher than that on CD5 super(-)B lymphocytes in untreated patients (P > 0.05), but lower than those of CD5 super(-)B lymphocytes in remission patients and NC (P < 0.05). CD86 on CD5 super(+)B lymphocytes of untreated patients was higher than that of remission patients (P < 0.05), NC (P < 0.01). CD86 on CD5 super(+)B lymphocytes of CLL was higher than that of NC, remission (P < 0.05), and untreated patients (P > 0.05). CD80 and CD86 on CD5 super(+)B lymphocytes was negatively correlated with hemoglobin (HB), C3, C4 (P < 0.05) and positively correlated with reticulocyte (Ret) (P < 0.05). CD69 on CD5 super(+) and CD5 super(-)B lymphocytes of CLL was higher than those of AIHA/Evans patients and NC (P < 0.05). The active molecules on CD5 super(+)B lymphocytes in peripheral blood of AIHA/Evans patients differ from those on CD5 super(-) and clonal CD5 super(+)B lymphocytes.